7 commercial, sales, and marketing predictions for 2023
pharmaphorum
DECEMBER 23, 2022
With these silos breaking down, biopharmas will have the opportunity to drive a more coordinated approach to HCP engagement using shared data and unified systems, while still maintaining compliance. This will force a shift in how companies think about incentive comp,” explains Dan Rizzo, VP, global business consulting leader. “In
92 
Let's personalize your content